IMS Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UMPQ
Umpqua Holdings Corp
UMPQ
|
+$1.16M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$1.13M |
| 3 |
Opko Health
OPK
|
+$1.03M |
| 4 |
Jabil
JBL
|
+$984K |
| 5 |
DO
Diamond Offshore Drilling
DO
|
+$956K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ScottsMiracle-Gro
SMG
|
+$835K |
| 2 |
KeyCorp
KEY
|
+$813K |
| 3 |
Starbucks
SBUX
|
+$783K |
| 4 |
PGH
Pengrowth Energy Corporation
PGH
|
+$776K |
| 5 |
First American
FAF
|
+$765K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.68% |
| 2 | Healthcare | 12.61% |
| 3 | Consumer Discretionary | 11.17% |
| 4 | Energy | 10.55% |
| 5 | Financials | 9.16% |
Similar funds
IMS Capital Management's Q4 2013 Portfolio in Review
As of Q4 2013, IMS Capital Management held 180 positions worth $79.5M, up 9.9% from $72.3M the previous quarter. Its ten largest holdings account for 19% of the portfolio.
IMS Capital Management deployed $3.94M of net new capital in Q4 2013, opening 39 new positions and adding to 48 existing holdings. Its largest new stake was Sarepta Therapeutics: 38,000 shares worth $774K.
By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 13% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was ScottsMiracle-Gro, an estimated $835K trimmed.
- IMS Capital Management's largest Q4 2013 buy was Sarepta Therapeutics: 38,000 shares worth $774K.
- IMS Capital Management added most to Umpqua Holdings Corp in Q4 2013, an estimated $1.16M increase.
- IMS Capital Management's biggest Q4 2013 reduction was ScottsMiracle-Gro, cutting an estimated $835K.
- IMS Capital Management fully exited KeyCorp in Q4 2013, selling an estimated $813K.
- IMS Capital Management's ten largest holdings make up 19% of its $79.5M portfolio in Q4 2013.
- IMS Capital Management opened 39 new positions and closed 31 in Q4 2013.
- IMS Capital Management's portfolio value rose 9.9% quarter-over-quarter to $79.5M.
Based on IMS Capital Management's 13F filing for Q4 2013, filed 5 Feb 2014.